Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model

This publication has 38 references indexed in Scilit:

• The Pharmacological Treatment of Pulmonary Arterial Hypertension
  Pharmacological Reviews, 2012
• Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
  European Respiratory Journal, 2010
• Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension
  Circulation, 2010
• Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure
  American Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
• Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
  European Heart Journal, 2009
• ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
  Circulation, 2009
• An epidemiological study of pulmonary arterial hypertension
  European Respiratory Journal, 2007
• Increased plasma monocyte chemoattractant protein‐1 level in idiopathic pulmonary arterial hypertension
  Respirology, 2006
• High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors
  Biochemical and Biophysical Research Communications, 2005
• Treatment of Pulmonary Arterial Hypertension
  New England Journal of Medicine, 2004